



4th Translational Research Conference

CHRONIC LYMPHOCYTIC LEUKAEMIA

March 5-7, 2026 – Stockholm, Sweden

Chairpersons: Jennifer Brown (Boston), Paolo Ghia (Milan), Michael Hallek (Cologne)

Thursday, March 5, 2026

08:30–08:40 **Welcome**

Conference Chairpersons

SESSION I – Spectrum of CLL - one disease or more

Chairs: Jennifer Brown (Boston), Sameer Parikh (Rochester)

08:40-08:55 MBL, in different forms (high vs low risk)

Julia Almeida (Salamanca)

08:55-09:00 *Discussion*

09:00-09:15 MBL, clinical implications (role of genetic abnormalities)
and management

Sameer Parikh (Rochester)

09:15-09:20 *Discussion*

09:20-09:35 Is stereotyped BCR ready to use in the clinics?

Andreas Agathangelidis (Athens)

09:35-09:40 *Discussion*

09:40-09:55 Chronic lymphocytic leukemia as a result of a monoclonal
selection process

Davide Bagnara (Genoa)

09:55-10:00 *Discussion*

10:00-10:07 Selected abstract as Brief oral communication

10:07-10:10 *Discussion*

10:10-10:40 *Panel discussion*

10:40-11:10 ***Coffee break***

SESSION II – Richter transformation

Chairs: Barbara Eichhorst (Cologne), Davide Rossi (Bellinzona)

11:10-11:25 Genomic characterization of RT

Davide Rossi (Bellinzona)

11:25-11:30 *Discussion*

Preliminary Programme – 2026.02.02

11:30-11:45	Prevention of evolution	Ferran Nadeu (Barcelona)
11:45-11:50	<i>Discussion</i>	
11:50-12:05	New RT recommendations	Adam Kittai (New York)
12:05-12:10	<i>Discussion</i>	
12:10-12:25	Novel therapies using checkpoint inhibitors and kinase inhibitors	Barbara Eichhorst (Cologne)
12:25-12:30	<i>Discussion</i>	
12:30-12:37	Selected abstract as Brief oral communication	
12:37-12:40	<i>Discussion</i>	
12:40-13:10	<i>Panel discussion</i>	
13:10-15:00	Lunch	
13:55-14:55	Satellite symposium slot	

SESSION III – Drivers of disease progression - from genetics, epigenetics, and proteomics (complexity of the evolution)
Chairs: Jennifer Brown (Boston), Christof Schneider (Ulm)

15:00-15:15	Clonal evolution of CLL	Speaker TBC
15:15-15:20	<i>Discussion</i>	
15:20-15:35	The CLL 10.000 project: value of the relevant genetic aberrations in CLL	Christof Schneider (Ulm)
15:35-15:40	<i>Discussion</i>	
15:40-15:55	Insights from SEQUOIA and ALPINE	Jennifer Brown (Boston)
15:55-16:00	<i>Discussion</i>	
16:00-16:07	Selected abstract as Brief oral communication	
16:07-16:10	<i>Discussion</i>	
16:10-16:40	<i>Panel discussion</i>	
16:40-17:10	Coffee break	

SESSION IV – The microenvironment of CLL
Chairs: Michael Hallek (Cologne), Martina Seiffert (Heidelberg)

17:10-17:25	T cells and the response to bispecific antibodies or CAR-T	Martina Seiffert (Heidelberg)
17:25-17:30	<i>Discussion</i>	
17:30-17:45	Extracellular vesicles and the communication of CLL cells with their microenvironment	Daniel Bachurski (Cologne)
17:45-17:50	<i>Discussion</i>	

Preliminary Programme – 2026.02.02

17:50-18:05	Proliferative reservoir in CLL: the dynamics of the cells	Nicholas Chiorazzi (Manhasset)
18:05-18:10	<i>Discussion</i>	
18:10-18:17	Selected abstract as Brief oral communication	
18:17-18:20	<i>Discussion</i>	
18:20-18:50	<i>Panel discussion</i>	
19:00-20:15	Mentored Poster Walks and Welcome Get-together Poster walk leaders: TBA	

Friday, March 6, 2026

08:00-09:00 Simultaneous Meet the Expert sessions

- 1. Selection of fixed duration therapy in front line CLL** William Wierda (Houston)
Barbara Eichhorst (Cologne)
- 2. One or two copies of *TP53*: does it matter?** Christof Schneider (Ulm)
- 3. Is there a need for in vitro screening systems?** Speaker TBC

09:10-10:10 *Satellite symposium slot*

10:10-10:35 *Coffee break*

SESSION V – Time limited therapies: which combination? which duration? which markers to stop therapy?

Chairs: Paolo Ghia (Milan), Kerry Rogers (Columbus)

10:35-10:50	MRD as a driver for treatment optimization (FLAIR)	Talha Munir (Leeds)
10:50-10:55	<i>Discussion</i>	
10:55-11:10	Lessons to be learned from the CLL17 trial	Othman Al-Sawaf (Cologne)
11:10-11:15	<i>Discussion</i>	
11:15-11:30	Amplify, Captivate, and other trials - lessons to be learned	Paolo Ghia (Milan)
11:30-11:35	<i>Discussion</i>	
11:35-11:42	Selected abstract as Brief oral communication	
11:42-11:45	<i>Discussion</i>	
11:45-12:15	<i>Panel discussion</i>	
12:15-14:10	<i>Lunch</i>	
13:00-14:00	<i>Satellite symposium slot</i>	

SESSION VI – BTK inhibition or degradation?

Chairs: Matthew Davids (Boston), Alessandra Tedeschi (Milan)

14:10-14:25	Role of BTK degraders in CLL	Justin Taylor (Miami)
14:25-14:30	<i>Discussion</i>	
	Debate:	
14:30-14:37	Continuous BTK inhibitor treatment is still the standard of care for most patients	Kerry Rogers (Columbus)
14:37-14:44	Fixed duration therapy is the standard of care with venetoclax combinations (Ven Obi or Ven BTKi)	Alessandra Tedeschi (Milan)
14:44-14:51	The therapeutic sequence is more relevant than the initial therapy	William Wierda (Houston)
14:51-15:31	<i>Roundtable discussion</i>	
15:31-16:00	<i>Coffee break</i>	

SESSION VII – The new challenge: resistance to one or two inhibitor classes? - Double refractory CLL

Chairs: Paula Cramer (Cologne), William Wierda (Houston)

16:00-16:15	Reinvigoration of T cells: strategies and tools for combination therapies	Alan Ramsay (London)
16:15-16:20	<i>Discussion</i>	
16:20-16:35	BTK resistance and mutations for different BTK inhibitors	Kerry Rogers (Columbus)
16:35-16:40	<i>Discussion</i>	
16:40-16:55	Venetoclax resistance	Matthew Davids (Boston)
16:55-17:00	<i>Discussion</i>	
17:00-17:15	What is the biology of double refractory CLL?	Lukas Frenzel (Cologne)
17:15-17:20	<i>Discussion</i>	
17:20-17:27	Selected abstract as Brief oral communication	
17:27-17:30	<i>Discussion</i>	
17:30-18:00	<i>Panel discussion</i>	

Saturday, March 7, 2026

08:00-09:00 Simultaneous Meet the Expert sessions

- | | |
|---|--|
| 1. Triple refractory: what to do? | Michael Hallek (Cologne) |
| 2. Sequencing after failing BTK inhibitors | Jennifer Brown (Boston)
Othman Al-Sawaf (Cologne) |

3. Preventive therapie in CLL

Paolo Ghia (Milan)

SESSION VIII – Future therapies, new compounds

Chairs: TBC

09:10-09:25	Novel modifiers of the apoptotic pathways	Gemma Kelly (Melbourne)*
09:25-09:30	<i>Discussion</i>	
09:30-09:45	T cell engagers and T cell dysfunction in CLL	Speaker TBC
09:45-09:50	<i>Discussion</i>	
09:50-10:05	Strategies to enhance the efficacy of CART cells in CLL	Jessica Peter (Würzburg)
10:05-10:10	<i>Discussion</i>	
10:10-10:25	BcR as a therapeutic target	Jean Lemoine (Philadelphia)
10:25-10:30	<i>Discussion</i>	
10:30-11:00	<i>Panel discussion</i>	
11:00-11:30	<i>Coffee break</i>	

SESSION IX – Directions and strategies to use the best agents in the optimal way: sequencing, combinations, costs of therapy, availability

Chairs: Jennifer Brown (Boston), Paolo Ghia (Milan), Michael Hallek (Cologne)

11:30-11:45	Do we need to perform trials on the optimal sequencing of therapeutic agents? How should they be designed?	Paula Cramer (Cologne)
11:45-11:50	<i>Discussion</i>	
11:50-12:05	When and how shall we bring new agents into 1L therapy?	Michael Hallek (Cologne)
12:05-12:10	<i>Discussion</i>	
12:10-12:25	What is the role of cellular immunotherapies in CLL? A critical summary and look into the future	Peter Dreger (Heidelberg)
12:25-12:30	<i>Discussion</i>	
12:30-13:00	Roundtable discussion: strategy to design future trials or therapies	
13:00-13:10	<i>Closing remarks</i>	Conference Chairpersons

MEETING CLOSURE

**pending confirmation*